At the end of November, the Supreme Administrative Court published a breakthrough judgment for the pharmaceutical sector in case 3 Afs 54/2020-73 Eli Lilly. That judgment concerned the provision of marketing services by a pharmaceutical distributor to a foreign entity belonging to the same group of companies in order to ensure profitability, which could not be achieved in a standard way because of price regulation.
Source Deloitte
